Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The Trump administration made a decidedly pro-industry statement on the Inflation Reduction Act (IRA). In an executive order issued Tuesday, President Donald Trump outlined changes to the Biden ...

Pfizer has halted the development of the experimental weight-loss pill danuglipron following a trial. A patient experienced a ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer (PFE) stock declined 1.5% in the pre-market trading session today, after the company discontinued the development of its experimental ...

Pfizer signage is displayed at the Pfizer NYC Headquarters, Thursday, April 10 ... and Novo Nordisk’s Wegovy are injectable, and drugmakers are eager to develop an easier-to-take pill version.